What Doctors Don't Tell YouStudies estimating the lifetime risk of women with the BRCA1 and BRCA2 genetic mutation developing breast cancer may have exaggerated the risk by only looking at high-risk families
Although BRCA2-positive women who use tamoxifen may be less likely to develop breast cancer than those using a placebo, BRCA1-positive women derive no protection from the drug.
